We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
Cap. Flow
+$85.4M
Cap. Flow %
7.49%
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.8M
2
HUM icon
Humana
HUM
+$19.1M
3
XLRN
Acceleron Pharma
XLRN
+$15.3M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$13.2M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$68.4M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.9M
3
BAX icon
Baxter International
BAX
+$10.1M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$8.54M
5
NVRO
NEVRO CORP.
NVRO
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.87%
2 Consumer Staples 0.6%
3 Consumer Discretionary 0.11%
4 Industrials 0.04%
5 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$129M 11.29%
15,239,444
– –
NBIX icon
2
Neurocrine Biosciences
NBIX
$15.6B
$108M 9.44%
2,720,967
+224,800
+9% +$8.92M
SRPT icon
3
Sarepta Therapeutics
SRPT
$2B
$74.8M 6.56%
3,833,128
+1,592,200
+71% +$27.8M
TSRO
4
DELISTED
TESARO, Inc.
TSRO
$48.4M 4.24%
1,098,659
+130,000
+13% +$5.22M
AGN
5
DELISTED
Allergan plc
AGN
$41.5M 3.64%
155,000
+10,000
+7% +$2.86M
TVTX icon
6
Travere Therapeutics
TVTX
$6.32B
$41M 3.59%
2,999,380
+420,000
+16% +$6.37M
XNCR icon
7
Xencor
XNCR
$2.18B
$24.2M 2.12%
1,804,784
-50,000
-3% -$592K
ARAV
8
DELISTED
Aravive, Inc. Common Stock
ARAV
$22.7M 1.99%
472,626
+89,384
+23% +$4.74M
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$21.2M 1.86%
803,036
+527,000
+191% +$15.3M
GBT
10
DELISTED
Global Blood Therapeutics, Inc.
GBT
$20.6M 1.8%
1,297,468
+110,838
+9% +$1.97M
HUM icon
11
Humana
HUM
$46.8B
$20.1M 1.77%
+110,000
New +$19.1M
NVRO
12
DELISTED
NEVRO CORP.
NVRO
$19.6M 1.72%
348,600
-135,679
-28% -$8M
QTNT
13
DELISTED
Quotient Limited Ordinary Shares
QTNT
$19.1M 1.68%
54,727
+32,388
+145% +$13.2M
TLPH icon
14
Talphera
TLPH
$63.8M
$18.5M 1.62%
299,788
– –
FPRX
15
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$18.5M 1.62%
454,129
+20,000
+5% +$687K
QURE icon
16
uniQure
QURE
$3.54B
$17.1M 1.5%
1,442,093
+475,000
+49% +$7.01M
MDVN
17
DELISTED
MEDIVATION, INC.
MDVN
$15.6M 1.37%
+340,000
New +$12.3M
LJPC
18
DELISTED
La Jolla Pharmaceutical Company
LJPC
$14.6M 1.28%
699,515
+50,000
+8% +$892K
IOVA icon
19
Iovance Biotherapeutics
IOVA
$3.82B
$14.2M 1.24%
2,787,256
-212,905
-7% -$1.17M
TEVA icon
20
Teva Pharmaceuticals
TEVA
$44.4B
$14M 1.23%
261,000
-220,000
-46% -$12.9M
DBVT
21
DBV Technologies
DBVT
$941M
$13.6M 1.19%
41,670
+10,998
+36% +$3.09M
VRTX icon
22
Vertex Pharmaceuticals
VRTX
$140B
$12.7M 1.12%
160,000
+50,000
+45% +$4.52M
CPXX
23
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
$12.1M 1.06%
+1,100,000
New +$3.61M
SRPT icon
24
CALL
Sarepta Therapeutics
SRPT
$2B
$10.7M 0.94%
550,000
+50,000
+10% +$874K
DERM
25
DELISTED
Dermira, Inc.
DERM
$10.6M 0.93%
512,000
+10,000
+2% +$245K
1
2 3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $85.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $12.9M trimmed.

  • Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
  • Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $12.9M.
  • Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
  • Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
  • Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.

Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.